The review found no eligible studies for this question.
It is very uncertain whether calcineurin inhibitor regimen changes complete remission compared with no calcineurin inhibitor regimen (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether calcineurin inhibitor regimen changes infection compared with no calcineurin inhibitor regimen (very low certainty).
It is very uncertain whether calcineurin inhibitor regimen changes malignancy compared with no calcineurin inhibitor regimen (very low certainty).
It is very uncertain whether calcineurin inhibitor changes treatment response at 3 to 6 months: partial remission compared with IV cyclophosphamide (very low certainty).
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete or partial remission compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete remission compared with IV cyclophosphamide (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in graft loss compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: CMV infection compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: malignancy compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in death compared with to standard dose CNI (moderate certainty).